INTRODUCTION {#s1}
============

Nearly 35% of adults aged 20 years and over were overweight in 2008, and 11% were obese according to the World Health Organization (WHO); this percentage will continue to increase with time. Roux-en-y-gastric bypass (RYGB) is the most common procedure done and leads to improvements in weight, sugar levels, insulin resistance, cardiovascular risk factors and sleep apnea. Although both short- and long-term complications of RYGB procedure have been recognized, including osteopenia, osteomalacia, and more rarely neurological disorders, the procedure has been deemed relatively safe and effective \[[@omw054C1]\].

Recent data suggest that modern bariatric procedures, such as RYGB, may also impart a 2-fold increased risk of nephrolithiasis, whereas 20--75% of patients may have hyperoxaluria, including 20% with very high urine oxalate levels, also putting them at considerable risk of oxalate nephropathy \[[@omw054C2]\].

CASE REPORT {#s2}
===========

We report a case of RYGB that leads to oxalate nephropathy 3 months after the procedure: a 51-year-old male patient with type 2 diabetes mellitus and a body mass index (BMI) of 42 kg/m^2^ (Table [1](#omw054TB1){ref-type="table"}). A standard RYGB procedure was performed, and a 30--50 ml gastric pouch was created; the length of the Roux segment was 150 cm, and the length of the jejunum from the ligament of Treitz to the jejuno-jejunal anastomosis was 40 cm. Table 1.Patient\'s demographics and biochemical resultsCharacteristicsSexMaleAge (year)51BMI (kg/m^2^)42Renal functionNormalDiabetes mellitusYesHypertensionNoHyperlipidemiaNoChronic obstructive pulmonary diseaseNoSmokerYesBiochemical results on admissionSerum creatinine (mg/dl)8.4224 h Urine oxalate level (mg)80

Three months after the procedure, the patient started complaining of productive cough, chills and bilateral flank pain over a period of 2 days associated with decreased fluid intake and low urine output. He was found to have elevated creatinine on laboratory workup (8.42 mg/dl). He was admitted for further investigation and was started on the appropriate antibiotics for the diagnosis of pneumonia. During history taking, the patient was found to be on non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen) and high-dose vitamin C, 1 g/day which is much higher than the normal dose (75 mg for women and 90 mg for men) on his own. His creatinine continued to increase during his stay at the hospital reaching 9.5 mg/dl and was oliguric. Twenty-four-hour urine oxalate level was 80 mg (normal range = 4--31 mg/24 h), and CT scan was done to rule out obstructive nephropathy. Kidney biopsy specimen was obtained, and it showed deposition of calcium oxalate crystals in the lumen of few tubules compatible with oxalate nephropathy (Fig. [1](#omw054F1){ref-type="fig"}). He was started on intravenous (IV) hydration, high oral calcium supplementation (1500 mg/day), low oxalate diet and steroid therapy (20 mg/day) as treatment for acute interstitial nephritis (AIN). After this regimen, the urine volume increased and his creatinine level decreased. Progressively creatinine decreased to reach 1.9 mg/dl 10 days after (Fig. [2](#omw054F2){ref-type="fig"}). During a period of 3 months, the patient got readmitted twice: once for gastroenteritis and once for bilateral lower limbs edema, and investigations revealed low total protein, albumin levels and generalized fatigue. For this reason, decision was taken to reverse the RYGB. Figure 1.Histopathology showed deposition of calcium oxalate crystals in the lumen of few tubules (black arrow). (A) Polarized light 50×. (B) Hematoxylin and eosin 50×. Figure 2.Serum creatinine level changes during hospital stay.

DISCUSSION {#s3}
==========

Oxalate nephropathy is a complication of RYGB that has been described earlier in the literature and will be encountered more frequently clinically, in our opinion, as the number of bariatric operations is increasing, especially RYGB. In the study done by Nasr *et al*. \[[@omw054C3]\], 11 patients presented with acute kidney injury (AKI) 6 months after RYGB and were diagnosed with oxalate nephropathy. In another study done by Sinha *et al*. \[[@omw054C1]\], 31 patients had oxalate nephropathy 2.2 years post RYGB. Oxalate nephropathy was seen also in kidney transplant recipient patients 27 and 7 years, respectively, after RYGB as described by Troxell *et al*. \[[@omw054C2]\]. Matlaga *et al*. \[[@omw054C4]\] showed that nephrolithiasis incidence after RYGB is 7.65% (in a study with 4639 RYGB patients) when compared with 4.63% in the same number of patients that did not undergo bariatric operation. Our patient presented with AKI (creatinine = 8.42 mg/dl) 3 months after the operation, which has never been reported before.

We think that the etiology of this early formation of oxalate deposits was multifactorial including: RYGB by itself as a malabsorptive factor, high dose of vitamin C intake, NSAIDs that the patient was taking to relieve the flank pain, high oxalate diet (coffee, chocolates, cocoa) and low fluid intake by the patient over 24 h that led to low urinary volumes.

According to several studies, the use of traditional NSAIDs is well established to be associated with AKI with relative risks compared with non-user ranging from 1.6 to 2.2. Indomethacin users account for the highest risk ratio of developing AKI. NSAIDs can cause AKI by two different mechanisms: hemodynamically mediated \[decrease in prostaglandin (PG) synthesis due to inhibition of cyclooxygenase (COX-1) enzymes in combination with renal vasoconstriction\] and AIN \[[@omw054C5]\].

Vitamin C is believed to result in a hyperoxaluric state. The recommended daily intake of vitamin C is between 75 and 90 mg/day. Several cases of oxalate nephropathy have been reported with vitamin C intake \<2 g/day \[[@omw054C6]\]. The mechanism of oxalate deposit formation is contributed by the increased fat malabsorption which leads to increased colonic fat that binds to free calcium, increasing unbound oxalate that is able to cross the colonic mucosa. In malabsorptive states (like after RYGB), the percentage of oxalate absorbed from the gut and excreted in urine can be markedly increased and hyperoxaluria often correlates with steatorrhea \[[@omw054C7]\].

The pathogenesis of hyperoxaluria after RYGB is not completely understood, but the length of the common channel is one of the most important factors leading to significant fat malabsorption in some, causing enteric hyperoxaluria. Although RYGB operation with a Roux limb of \<150 cm in length is generally believed not to cause fat malabsorption, data suggest that hyperoxaluria may indeed occur, and represent a risk for calcium oxalate nephrolithiasis \[[@omw054C1]\].

Some earlier studies of patients with inflammatory bowel disease correlate the degree of hyperoxaluria with the degree of steatorrhea; this pathogenesis might explain why patients who have had distal RYGB (through creation of a longer Roux limb and subsequently shorter common channel for nutrient absorption) can be at higher risk for developing calcium oxalate kidney stones compared with standard RYGB patients \[[@omw054C8]\].

The goal of management is to reach normal creatinine levels and normal diuresis. Many treatments can be applied starting with oxalate-free diet, limit fat intake, appropriate hydration to maintain urine output of at least 2 l, oral calcium supplementation and reversal of the surgery \[[@omw054C9]\]. This strategy, if applied early, can reverse the nephropathy and can prevent irreversible tubular damage leading to dialysis. More recent treatments like supplementation of *Oxalobacter formigenes* bacteria*,* a normal commensurate part of the human gut microflora which metabolizes oxalate as an energy source have been applied and showed promising results by reducing the urinary oxalate levels \[[@omw054C1]\].

In conclusion, surgeons should be aware of this complication and be aggressive in their treatment strategies in order not to reach dialysis. We suggest counting accurately the length of the common channel during each gastric bypass as well as maintaining oxalate-free and fat-free diet with oral calcium supplementation postoperatively.
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